Preliminary cold dosing by unlabeled daratumumab for saturation of FcRn receptors allows redistributing further injected radioconjugates towards cancer cells, however, it is as well associated with the risk of prolonged saturation of CD38 by antibodies devoid of radionuclides. The gene discussed is CD38; the disease is cancer.